Advertisement

FDG PET in the evaluation of phaeochromocytoma: a correlative study with MIBG scintigraphy and Ki-67 proliferative index

Published:September 16, 2013DOI:https://doi.org/10.1016/j.clinimag.2013.07.011

      Abstract

      To compare 123I-metaiodobenzylguanidine (MIBG) and [Fluorine-18]-2-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET) in 22 patients with phaeochromocytomas and paragangliomas (PGL) retrospectively and to evaluate the correlation between FDG uptake and Ki-67 proliferative index. Fourteen of 17 (82%) patients at initial diagnosis had positive FDG uptake, more intensely in PGL. Eleven of 12 (92%) patients had positive MIBG uptake. PET and MIBG scintigraphy were concordant in 10 patients, discordant in 6. Combined results yielded no false negative findings and are complementary. Neither maximum standardised uptake value nor visual scores on MIBG correlated with Ki-67.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Imaging
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Reisch N
        • Peczkowska M
        • Januszewicz A
        • Neumann HPH
        Pheochromocytoma: presentation, diagnosis and treatment.
        J Hypertens. 2006; 24: 2331-2339
        • Strosberg JR
        Update on the management of unusual neuroendocrine tumors: pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma.
        Semin Oncol. 2013; 40: 120-133
        • Gross MD
        • Avram A
        • Fig LM
        • Rubello D
        Contemporary adrenal scintigraphy.
        Eur J Nucl Med Mol Imaging. 2007; 34: 547-557
        • Lin M
        • Shon IH
        • Lin P
        Positron emission tomography: current status and future challenges.
        Intern Med J. 2010; 40: 19-29
        • Shulkin BL
        • Thompson NW
        • Shapiro B
        • Francis IR
        • Sisson JC
        Pheochromocytomas: Imaging with 2-[Fluorine-18]fluoro-2-deoxy-d-glucose PET.
        Radiology. 1999; 212: 35-41
        • Ezuddin S
        • Fragkaki C
        MIBG and FDG PET findings in a patient with malignant pheochromocytoma: a significant discrepancy.
        Clin Nucl Med. 2005; 30: 579-581
        • Mamede M
        • Carrasquillo JA
        • Chen CC
        • Del Corral P
        • Whatley M
        • Ilias I
        • Ayala A
        • Pacak K
        Discordant localization of 2-[18F]-fluoro-2-deoxy-d-glucose in 6-[18F]-fluorodopamine- and [123I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites.
        Nucl Med Commun. 2006; 27: 31-36
        • Salmenkivi K
        • Heikkilä P
        • Haglund C
        • Louhimo J
        • Arola J
        Lack of histologically suspicious features, proliferative activity, and p53 expression suggests benign diagnosis in phaeochromocytomas.
        Histopathology. 2003; 43: 62-71
        • Ayala-Ramirez M
        • Feng L
        • Johnson MM
        • Ejaz S
        • Habra MA
        • Rich T
        • Busaidy N
        • Cote GJ
        • Perrier N
        • Phan A
        • Patel S
        • Waguespack S
        • Jimenez C
        Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
        J Clin Endocrinol Metab. 2011; 96: 717-725
        • Timmers HJLM
        • Kozupa A
        • Chen CC
        • Carrasquillo JA
        • Ling A
        • Eisenhofer G
        • Adams KT
        • Solis D
        • Lenders JWM
        • Pacak K
        Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.
        J Clin Oncol. 2007; 25: 2262-2269
        • Luster M
        • Karges W
        • Zeich K
        • Pauls S
        • Verburg FA
        • Dralle H
        • Glatting G
        • Buck AK
        • Solbach C
        • Neumaier B
        • Reske SN
        • Mottaghy FM
        Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma.
        Eur J Nucl Med Mol Imaging. 2010; 37: 484-493
        • Kaji P
        • Carrasquillo JA
        • Linehan WM
        • Chen CC
        • Eisenhofer G
        • Pinto PA
        • Lai EW
        • Pacak K
        The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel–Lindau syndrome.
        Eur J Endocrinol. 2007; 156: 483-487
        • Mann GN
        • Link JM
        • Pham P
        • Pickett CA
        • Byrd DR
        • Kinahan PE
        • Krohn KA
        • Mankoff DA
        [11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma.
        Ann Surg Oncol. 2006; 13: 187-197
        • Mozley PD
        • Kim CK
        • Mohsin J
        • Jatlow A
        • Gosfield E
        • Alavi A
        The efficacy of Iodine-123-MIBG as a screening test for pheochromocytoma.
        J Nucl Med. 1994; 35: 1138-1144
        • Taïeb D
        • Timmers H
        • Hindié E
        • Guillet B
        • Neumann H
        • Walz M
        • Opocher G
        • Herder W
        • Boedeker C
        • Krijger R
        • Chiti A
        • Al-Nahhas A
        • Pacak K
        • Rubello DEANM
        2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma.
        Eur J Nucl Med Mol Imaging. 2012; 39: 1977-1995
        • Taïeb D
        • Neumann H
        • Rubello D
        • Al-Nahhas A
        • Guillet B
        • Hindié E
        Modern nuclear imaging for paragangliomas: beyond SPECT.
        J Nucl Med. 2012; 53: 264-274
        • Timmers HJLM
        • Chen CC
        • Carrasquillo JA
        • Whatley M
        • Ling A
        • Havekes B
        • Eisenhofer G
        • Martiniova L
        • Adams KT
        • Pacak K
        Comparison of 18F-Fluoro-l-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.
        J Clin Endocrinol Metab. 2009; 94: 4757-4767